Affitech and Peregrine in antibody agreement

Published: 1-Aug-2003


US biopharmaceutical company Peregrine Pharmaceuticals and antibody therapeutics company Affitech, of Oslo in Norway, are to collaborate on the production of human antibodies for Peregrine's Vascular Targeting Agent (VTA) and antiangiogenesis programmes. Peregrine will provide targets and Affitech will apply its human antibody libraries and its proprietary discovery and screening technologies, including its AffiScreen platform, to generate a panel of fully human antibodies against the targets.

The agreement allows flexibility for the development of any clinical candidates that are generated, including joint development, internal development at Peregrine or Affitech, or out-licensing to a third party. 'We believe we will be able to have several VTAs in the clinic with unique target and effector functions,' said Steven King, president and ceo of Peregrine Pharmaceuticals.

You may also like